Review Article

Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use

Table 1

Worldwide prevalence of fluoroquinolone-resistant uropathogens. Data in columns four and five represent total numbers of isolates studied; data in columns six to nine represent fluoroquinolone-resistant isolates in percent of total; figures in column ten show ESBL-positive isolates in percent of total isolates studied; figures in columns eleven and twelve represent ESBL-positive or negative fluoroquinolone-resistant isolates in percent of total numbers of ESBL-positive isolates.

SpeciesCountrySampling period uUTI cUTIHAUTIHAUTICAUTICAUTIESBL pos
% FQ res. % FQ res. Ref.
uUTIcUTIuUTIcUTI% ofof ESBLof ESBL
% FQ res.% FQ res.% FQ res.% FQ res.totalpos.neg

E. coliESP03/03 to 01/03828219.58.5[482]
E. coliGRC01/05 to 03/061.9362.2[483]
E. coli PRT03/04 to 03/06909896100[120]
E. coliTUR2005 to 200610725.2[484]
S. aureusTUR2005 to 20061241.7[484]
Enterococcus spp.TUR2005 to 2006520.0[484]
E. coliTUR01/07 to 12/072693422.041.0[90]
E. coliTUR32129017.038.0717.992.1[485]
E. coliTUR11015.0[486]
E. coliLBN200039517.0[487]
E. coliLBN200962848.0[487]
E. coliIND08/04 to 07/056169.034.465.6[488]
K. pneumoniaeIND08/04 to 07/052247.027.372.7[488]
E. coliIND06/05 to 12/0550829.170.9[489]
K. pneumoniaeIND06/05 to 12/0564.225.674.4[489]
Enterobacter sppIND06/05 to 12/0528.671.4[489]
E. coliIND06/04 to 06/054129242.457.6[94]
K. pneumoniaeIND06/04 to 06/051363315.284.8[94]
Gram-neg. bacilli IND09/01 to 12/0179377.571.528.5[490]
Gram pos. cocci IND09/01 to 12/027847.6[490]
E. coliIND03/11 to 08/1153221[491]
E. coliIND01/10 to 08/108962[492]
Klebsiella spp.IND01/10 to 08/103248[492]
E. coliPAK04/05 to 02/0611662.180.356.843.2[493]
E. coliPAK05/07 to 09/0927677.2[494]
E. coliIRN03/09 to 06/0962031[495]
K. pneumoniaeIRN03/09 to 06/0911515[495]
Enterococcus spp.IRN03/09 to 06/0911059[495]
P. aeruginosaIRN03/09 to 06/093023[495]
S. aureusIRN03/09 to 06/09810.06[495]
E. coliPRK200630123.410011.8[89]
E. coliPRK68871.812.187.9[496]
E coliPRK16071.823.176.9[496]
E. coliPRK01/08 to 06/091.99425.4[497]
E. coliPRK01/01 to 12/02 12.721.2[498]
E. coliPRK01/08 to 12/09 8830.6[498]
E. coli HKG2006 to 200827112.95.294.8[499]
E. coli ZAF11/05 to 10/068711.52.697.4[500]
E. coliZAF11/05 to 10/0636617.211.988.1[500]
K. pneumoniaeZAF11/05 to 10/061711.831.368.7[500]
K. pneumoniaeZAF11/05 to 10/0618231.940.659.4[500]
E. coliFRA05/03 to 04/041.2173.7[501]
E. coliESP2002 + 20045.73722.7[502]
E. coliESP11/03 to 10/043.29218.0[503]
E. coliRUS1998 to 20014564.5[504]
E. coliGBR1999 to 20001.2912.3[505]
E. coliISR19996.6926.01.2598.75[506]
E. coliUSA08/08 to 03/0925338[506]
E. coliUSA1022.0[507]
E. coliUSA08/08 to 03/0935710.038.0[109]
E. coliNLD199733229.0[111]
Proteus spp.NLD199717122.0[111]
E. coli2004 + 20095653.0[508]
E. coliNLD01/04 to 12/0942012.0[130]
E. coliCHE01/06 to 08/0734522.0[509]
E. coliCAN09/05 to 06/0628319.83.596.5[263]
P. aeruginosaCAN09/05 to 06/064537.8[263]
K. pneumoniaeCAN09/05 to 06/06510.01.898.2[263]
E. cloacaeCAN09/05 to 06/06166.3[263]
MSSACAN09/05 to 06/062020.0[263]
E. coliCAN01/08 to 12/0851021.44.995.1[264]
K. pneumoniaeCAN01/08 to 12/089812.23.296.8[264]

uUTI: uncomplicated urinary tract infection; cUTI: complicated urinary tract infection; HA-UTI: Healthcare associated urinary tract infection; CA-UTI: community acquired urinary tract infection; ESBL: extended spectrum β-lactamase; Ref: reference; *total number of isolates studied in both sampling periods; ESP: Spain; GRC: Greece; PRT: Portugal; TUR: Turkey; LBN: Lebanon; IND: India; PAK: Pakistan; PRK: South Korea; HKG: Hong Kong; ZAF: South Africa; RUS: Russian Federation; USA: United States of America; NLD: The Netherlands; CHE: Switzerland; CAN: Canada.